Alpha-1 Antitrypsin Deficiency Market Snapshot (2023 to 2033)

The Global Alpha-1 Antitrypsin Deficiency Industry is expected to reach a valuation of US$10 billion by 2033, from a predicted US$3 billion in 2023. This indicates that the industry is poised for revolutionary growth. Future Market Insights (FMI) has shown this impressive trajectory, which has a strong compound annual growth rate (CAGR) of 12.8% during the projected timeframe.

There are two main factors behind this increase. First, the incidence of respiratory diseases has noticeably increased worldwide. Second, there has been a notable increase in the use of augmentation treatment. The protein Alpha-1 Antitrypsin (AAT) is extracted from healthy donors’ blood plasma and used in augmentation treatment. Patients are then given this extracted AAT to increase the amounts of AAT in their respiratory systems. As a result, the advancement of emphysema is slowed down. A reduction in the recurrence of exacerbations, and a shortened recovery time.

Medical professionals and patients alike are increasingly recognizing the efficacy of augmentation therapy, contributing to the burgeoning demand for Alpha-1 Antitrypsin Deficiency treatments. FMI’s comprehensive analysis underscores the growing significance of this therapeutic approach, positioning it as a cornerstone for the market’s upward trajectory.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16288

Key Takeaways from the Global Alpha-1 Antitrypsin Deficiency Industry Study

The global alpha-1 antitrypsin insufficiency market is expected to develop at a 12.8% CAGR by 2033, according to FMI.
The global market for Alpha-1 Antitrypsin Deficiency is anticipated to be over US$ 3 billion.
The global market for Alpha-1 Antitrypsin Deficiency is expected to be around US$ 10 billion.
According to Future Market Insights, Asia Pacific will grow at a CAGR of 12% between 2023 and 2033.
North America is expected to grow at a 12.7% CAGR between 2023 and 2033.
Europe is expected to grow at a 12.3% CAGR between 2023 and 2033.

“Within North America, the United States has dominated the market. The rising number of government funding, developments in gene therapy research and development, and the rising penetration of target illnesses are the primary drivers driving the Alpha-1 Antitrypsin Deficiency market expansion,” says an analyst at FMI

Global Alpha-1 Antitrypsin Deficiency Industry Competition

To address the present patient pool’s requests and counter the therapeutic market’s unmet needs, drug developers are increasingly moving their focus to alpha-1 antitrypsin deficiency (AATD).

Many novel medicines are being developed by several businesses, including ARO-AAT (Arrowhead Pharmaceutical), Alvelestat (Mereo Biopharma), and Inhaled AAT (Kamada).

ARO-AAT (Arrowhead Pharmaceutical) is a second-generation subcutaneously given drug that lowers hepatic synthesis of the mutant AAT protein by knocking down the alpha-1 antitrypsin (AAT) gene transcript. The business is now undertaking Phase II clinical studies to assess the drug’s safety, tolerability, and pharmacodynamic impact in AATD patients.

Elevate your understanding with our insightful methodology now. @
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16288

Key players in the Global Alpha-1 Antitrypsin Deficiency Industry are:

Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
LFB Biomedicaments

Global Alpha-1 Antitrypsin Deficiency Industry Recent Developments:

Kamada Ltd., a vertically integrated global biopharmaceutical company focused on specialty plasma-derived therapeutics, announced in October 2022 that it had been awarded a three-year extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four IgG products, CYTOGAM®, HEPAGAM®, VARIZIG®, and WINRHO® SDF, for a total estimated value of US$ 22 million. This award ensures that such products will continue to be sold in Canada. In November 2021, Kamada purchased four commercial pharmaceuticals that have been licensed by Health Canada and the United States Food and Drug Administration (FDA).

Key Segments Profiled in the Global Alpha-1 Antitrypsin Deficiency Industry Survey

By Product Type: